CA3248329A1 - Antibodies binding to gprc5d - Google Patents
Antibodies binding to gprc5dInfo
- Publication number
- CA3248329A1 CA3248329A1 CA3248329A CA3248329A CA3248329A1 CA 3248329 A1 CA3248329 A1 CA 3248329A1 CA 3248329 A CA3248329 A CA 3248329A CA 3248329 A CA3248329 A CA 3248329A CA 3248329 A1 CA3248329 A1 CA 3248329A1
- Authority
- CA
- Canada
- Prior art keywords
- gprc5d
- antibodies binding
- antibodies
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19189255.3 | 2019-07-31 | ||
| EP19189255 | 2019-07-31 | ||
| CA3144524A CA3144524C (en) | 2019-07-31 | 2020-07-28 | GPRC5D-BINDING ANTIBODIES |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3144524A Division CA3144524C (en) | 2019-07-31 | 2020-07-28 | GPRC5D-BINDING ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3248329A1 true CA3248329A1 (en) | 2025-11-29 |
Family
ID=67513452
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3144524A Active CA3144524C (en) | 2019-07-31 | 2020-07-28 | GPRC5D-BINDING ANTIBODIES |
| CA3248329A Pending CA3248329A1 (en) | 2019-07-31 | 2020-07-28 | Antibodies binding to gprc5d |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3144524A Active CA3144524C (en) | 2019-07-31 | 2020-07-28 | GPRC5D-BINDING ANTIBODIES |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220259318A1 (en) |
| EP (1) | EP4003526A2 (en) |
| JP (3) | JP2022543553A (en) |
| KR (1) | KR20220028035A (en) |
| CN (2) | CN119192386A (en) |
| AR (1) | AR119553A1 (en) |
| AU (1) | AU2020323686B2 (en) |
| BR (1) | BR112022001460A2 (en) |
| CA (2) | CA3144524C (en) |
| CL (2) | CL2022000127A1 (en) |
| CO (1) | CO2022000803A2 (en) |
| CR (1) | CR20220019A (en) |
| IL (1) | IL287613A (en) |
| MX (1) | MX2022001156A (en) |
| MY (1) | MY206610A (en) |
| PE (1) | PE20220394A1 (en) |
| SG (1) | SG11202112491WA (en) |
| TW (1) | TWI868189B (en) |
| WO (1) | WO2021018859A2 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102461885B1 (en) | 2017-04-03 | 2022-11-03 | 에프. 호프만-라 로슈 아게 | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| SG11202102859TA (en) | 2018-12-21 | 2021-04-29 | Hoffmann La Roche | Antibodies binding to cd3 |
| CR20220637A (en) | 2020-06-19 | 2023-01-31 | Hoffmann La Roche | ANTIBODIES THAT BIND CD3 AND CD19 |
| AU2021346129A1 (en) * | 2020-09-16 | 2023-06-01 | Janssen Biotech, Inc. | Methods for treating multiple myeloma |
| WO2022129120A1 (en) | 2020-12-17 | 2022-06-23 | F. Hoffmann-La Roche Ag | Anti-hla-g antibodies and use thereof |
| WO2022179970A1 (en) | 2021-02-24 | 2022-09-01 | F. Hoffmann-La Roche Ag | Regeneration and multiple use of depth filters |
| AU2022246607A1 (en) * | 2021-03-31 | 2023-11-16 | Janssen Biotech, Inc. | Materials and methods for immune effector cells redirection |
| WO2022247804A1 (en) * | 2021-05-23 | 2022-12-01 | 上海祥耀生物科技有限责任公司 | Anti-gprc5d antibody, preparation method therefor, and use thereof |
| JP2024540148A (en) * | 2021-11-05 | 2024-10-31 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | Antibodies that bind to GPRC5D and uses thereof |
| CN116375868A (en) * | 2021-12-31 | 2023-07-04 | 康源博创生物科技(北京)有限公司 | A kind of anti-CD3 humanized antibody and its application in the preparation of bispecific antibody |
| MX2024011128A (en) * | 2022-03-14 | 2024-09-18 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Antigen-binding molecule specifically binding to gprc5d and cd3 and medical use thereof. |
| KR20250028447A (en) * | 2022-06-30 | 2025-02-28 | 키메드 바이오사이언시스 (청두) 컴퍼니 리미티드 | Development and application of novel multi-specific tumor suppressors |
| CN119698434A (en) * | 2022-07-21 | 2025-03-25 | 山东先声生物制药有限公司 | Anti-GPRC5D nanoantibodies and their applications |
| EP4565262A2 (en) | 2022-08-05 | 2025-06-11 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
| TW202423969A (en) | 2022-10-10 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | Combination therapy of a gprc5d tcb and proteasome inhibitors |
| TW202430211A (en) | 2022-10-10 | 2024-08-01 | 瑞士商赫孚孟拉羅股份公司 | Combination therapy of a gprc5d tcb and imids |
| TW202423970A (en) | 2022-10-10 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | Combination therapy of a gprc5d tcb and cd38 antibodies |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| CN120476149A (en) * | 2022-12-23 | 2025-08-12 | 成都恩沐生物科技有限公司 | Multispecific peptide complex targeting GPRC5D |
| EP4777540A1 (en) * | 2023-09-13 | 2026-07-22 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025147545A1 (en) | 2024-01-03 | 2025-07-10 | Juno Therapeutics, Inc. | Lipid nanoparticles for delivery of nucleic acids and related methods and uses |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| US12545726B1 (en) | 2025-07-22 | 2026-02-10 | Integral Molecular, Inc. | Compositions and methods related to GPRC5D binding agents and variants thereof |
Family Cites Families (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2808353C2 (en) | 1977-04-18 | 1984-01-19 | Hitachi Metals, Ltd., Tokyo | Earring |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| FI903489A7 (en) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligands containing one moiety, receptors containing these ligands, methods for their preparation and uses of the ligands and receptors |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69129154T2 (en) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
| FI941572L (en) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Combination and method of use of anti-erbB-2 monoclonal antibodies |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| ATE139900T1 (en) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES AGAINST HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR THE TREATMENT OF B CELL LYMPHOMA |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| JP2002506353A (en) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | Methods and compositions for galactosylated glycoproteins |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| CA2307166A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| JP4334141B2 (en) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | Engineering glycosylation of antibodies to improve antibody-dependent cytotoxicity |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| KR100797667B1 (en) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | How to regulate transcription of foreign genes |
| JP2003516755A (en) | 1999-12-15 | 2003-05-20 | ジェネンテック・インコーポレーテッド | Shotgun scanning, a combined method for mapping functional protein epitopes |
| PT2857516T (en) | 2000-04-11 | 2017-08-28 | Genentech Inc | Multivalent antibodies and uses therefor |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DE60131456T2 (en) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | TRANCHROMOSOMAL TRANSGEN RODENTS FOR THE MANUFACTURE OF HUMAN ANTIBODIES |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
| PL213948B1 (en) | 2001-10-25 | 2013-05-31 | Genentech Inc | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR ENHANCING ACTIVITY OF BINDING ANTIBODY COMPOSITION WITH FC GAMMA IIIA RECEPTOR |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PRODUCING ANTIBODY COMPOSITION |
| WO2003085102A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| WO2003084570A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM |
| KR20050000380A (en) | 2002-04-09 | 2005-01-03 | 교와 핫꼬 고교 가부시끼가이샤 | Cells with modified genome |
| EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and uses thereof |
| AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| KR101498588B1 (en) | 2003-01-22 | 2015-03-05 | 로슈 글리카트 아게 | FUSION CONSTRUCTS AND USE OF SAME TO PRODUCE ANTIBODIES WITH INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION |
| AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| CN1961003B (en) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | Humanized anti-TGF-beta antibodies |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| TR201808537T4 (en) | 2004-09-23 | 2018-07-23 | Genentech Inc | Cysteine modified antibodies and conjugates. |
| BRPI0607315B1 (en) | 2005-02-07 | 2022-05-17 | Roche Glycart Ag | Humanized anti-egfr antigen binding molecule and its uses, pharmaceutical composition, and method for detecting the presence of egfr in a sample |
| KR101374454B1 (en) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | Methods for producing polypeptides by regulating polypeptide association |
| US8236308B2 (en) | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| DK1999154T3 (en) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | MANUFACTURED HETERODIMERED PROTEIN DOMAINS |
| EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| US20080044455A1 (en) | 2006-08-21 | 2008-02-21 | Chaim Welczer | Tonsillitus Treatment |
| EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| BRPI1014089A2 (en) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | multispecific antibodies comprising full length antibodies and single chain fab fragments |
| PT2417156E (en) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Trivalent, bispecific antibodies |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| SG176219A1 (en) | 2009-05-27 | 2011-12-29 | Hoffmann La Roche | Tri- or tetraspecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| CN102712696A (en) | 2009-09-16 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | Protein complexes comprising coiled-coils and/or tethers and uses thereof |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| CA3220104A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| CN103429620B (en) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | Antibody design for stable heterodimerization with mutations in the Fc domain |
| LT2691417T (en) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antibody fc variants |
| LT2748201T (en) | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| KR101721301B1 (en) | 2011-08-23 | 2017-03-29 | 로슈 글리카트 아게 | Bispecific antigen binding molecules |
| KR101870555B1 (en) | 2011-08-23 | 2018-06-22 | 로슈 글리카트 아게 | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| KR102069397B1 (en) | 2012-02-15 | 2020-01-22 | 에프. 호프만-라 로슈 아게 | Fc-receptor based affinity chromatography |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| WO2014131694A1 (en) * | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| CN110437337B (en) | 2013-02-26 | 2024-07-30 | 罗切格利卡特公司 | Bispecific T cell activating antigen binding molecules |
| CA2904806C (en) * | 2013-04-29 | 2021-11-23 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
| BR112016011027A2 (en) | 2013-12-20 | 2017-12-05 | Genentech Inc | method of producing an antibody, antibodies, pharmaceutical composition, polynucleotide, vector, host cell, method of treating asthma and method of treating a disorder |
| UA117289C2 (en) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | MULTISPECIFIC ANTIBODY |
| EP3174897B1 (en) | 2014-07-29 | 2020-02-12 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
| PL3177643T3 (en) | 2014-08-04 | 2019-09-30 | F.Hoffmann-La Roche Ag | Bispecific t cell activating antigen binding molecules |
| JP2017531620A (en) | 2014-09-12 | 2017-10-26 | ジェネンテック, インコーポレイテッド | Cysteine engineered antibodies and conjugates |
| JP2017536341A (en) * | 2014-10-09 | 2017-12-07 | エンクマフ アーゲー | Bispecific antibodies against CD3ε and ROR1 for use in the treatment of ovarian cancer |
| JP6829194B2 (en) | 2014-10-24 | 2021-02-10 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Method of antibody humanization based on VH-VL domain angle |
| AU2015357535B2 (en) | 2014-12-05 | 2020-05-14 | Eureka Therapeutics, Inc. | Antibodies targeting G-protein coupled receptor and methods of use |
| HUE057285T2 (en) | 2015-04-13 | 2022-04-28 | Pfizer | Therapeutic antibodies and their uses |
| CA2980189A1 (en) | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Multispecific antigen-binding proteins |
| TWI781108B (en) * | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof |
| CN109843926B (en) * | 2016-09-30 | 2023-01-20 | 豪夫迈·罗氏有限公司 | Bispecific antibodies against CD3 |
| WO2018117786A1 (en) | 2016-12-19 | 2018-06-28 | Campo Y Ramos Juan Carlos | Method for scientific self-adjusting moulding based on real-time recurrent learning |
| TW201837174A (en) * | 2017-02-07 | 2018-10-16 | 日商第一三共股份有限公司 | Anti-gprc5d antibody and molecule comprising the antibody |
| EP3704155A2 (en) * | 2017-11-01 | 2020-09-09 | F. Hoffmann-La Roche AG | Combination therapy with targeted ox40 agonists |
| TWI829667B (en) * | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | Antibodies binding to gprc5d |
| WO2019220368A1 (en) * | 2018-05-16 | 2019-11-21 | Janssen Biotech, Inc. | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
| SG11202102859TA (en) * | 2018-12-21 | 2021-04-29 | Hoffmann La Roche | Antibodies binding to cd3 |
| CR20210326A (en) * | 2018-12-21 | 2021-09-10 | Hoffmann La Roche | CD28 ANTIGEN BINDING AGONIST MOLECULES ACTING ON THE TUMOR |
| JP7905331B2 (en) * | 2020-10-15 | 2026-08-14 | インターベット インターナショナル ベー. フェー. | Canine antibodies against canine interleukin-31 receptor alpha |
-
2020
- 2020-07-28 JP JP2022505423A patent/JP2022543553A/en active Pending
- 2020-07-28 CN CN202411038289.6A patent/CN119192386A/en active Pending
- 2020-07-28 MY MYPI2022000553A patent/MY206610A/en unknown
- 2020-07-28 CA CA3144524A patent/CA3144524C/en active Active
- 2020-07-28 CN CN202080054556.2A patent/CN114174342B/en active Active
- 2020-07-28 CA CA3248329A patent/CA3248329A1/en active Pending
- 2020-07-28 BR BR112022001460A patent/BR112022001460A2/en unknown
- 2020-07-28 EP EP20749834.6A patent/EP4003526A2/en active Pending
- 2020-07-28 CR CR20220019A patent/CR20220019A/en unknown
- 2020-07-28 WO PCT/EP2020/071182 patent/WO2021018859A2/en not_active Ceased
- 2020-07-28 AU AU2020323686A patent/AU2020323686B2/en active Active
- 2020-07-28 SG SG11202112491WA patent/SG11202112491WA/en unknown
- 2020-07-28 MX MX2022001156A patent/MX2022001156A/en unknown
- 2020-07-28 PE PE2022000110A patent/PE20220394A1/en unknown
- 2020-07-28 KR KR1020227003120A patent/KR20220028035A/en not_active Ceased
- 2020-07-29 TW TW109125498A patent/TWI868189B/en active
- 2020-07-31 AR ARP200102166A patent/AR119553A1/en unknown
-
2021
- 2021-10-27 IL IL287613A patent/IL287613A/en unknown
-
2022
- 2022-01-19 CL CL2022000127A patent/CL2022000127A1/en unknown
- 2022-01-28 CO CONC2022/0000803A patent/CO2022000803A2/en unknown
- 2022-01-28 US US17/586,977 patent/US20220259318A1/en active Pending
-
2023
- 2023-08-18 JP JP2023133671A patent/JP7679430B2/en active Active
-
2024
- 2024-03-19 CL CL2024000802A patent/CL2024000802A1/en unknown
-
2025
- 2025-05-07 JP JP2025077618A patent/JP2025131586A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022000127A1 (en) | 2022-10-28 |
| PE20220394A1 (en) | 2022-03-18 |
| TW202112823A (en) | 2021-04-01 |
| US20220259318A1 (en) | 2022-08-18 |
| JP2025131586A (en) | 2025-09-09 |
| AU2020323686B2 (en) | 2024-03-21 |
| CO2022000803A2 (en) | 2022-02-07 |
| AU2020323686A1 (en) | 2021-11-11 |
| BR112022001460A2 (en) | 2022-03-22 |
| EP4003526A2 (en) | 2022-06-01 |
| AR119553A1 (en) | 2021-12-29 |
| CA3144524A1 (en) | 2021-02-04 |
| JP7679430B2 (en) | 2025-05-19 |
| IL287613A (en) | 2021-12-01 |
| WO2021018859A3 (en) | 2021-05-14 |
| TWI868189B (en) | 2025-01-01 |
| CR20220019A (en) | 2022-02-11 |
| WO2021018859A2 (en) | 2021-02-04 |
| CN114174342A (en) | 2022-03-11 |
| JP2023175704A (en) | 2023-12-12 |
| MX2022001156A (en) | 2022-02-22 |
| CL2024000802A1 (en) | 2024-07-19 |
| CN119192386A (en) | 2024-12-27 |
| CN114174342B (en) | 2024-08-16 |
| CA3144524C (en) | 2025-12-02 |
| JP2022543553A (en) | 2022-10-13 |
| MY206610A (en) | 2024-12-26 |
| KR20220028035A (en) | 2022-03-08 |
| SG11202112491WA (en) | 2021-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287613A (en) | Antibodies binding to gprc5d | |
| IL276537A (en) | Antibodies binding to gprc5d | |
| SG11202102859TA (en) | Antibodies binding to cd3 | |
| EP3986936A4 (en) | Anti-tigit antibodies | |
| EP3817772A4 (en) | Antigen binding constructs to cd4 | |
| EP4081546A4 (en) | Novel anti-fgfr2b antibodies | |
| IL286398A (en) | Heavy chain antibodies binding to psma | |
| EP3931223A4 (en) | Antibody binding to pd-1 | |
| EP4083211A4 (en) | Anti-cdcp1 antibody | |
| AU2020243430A1 (en) | Antigen binding proteins | |
| EP3917965A4 (en) | Novel anti-ifnar1 antibodies | |
| EP3986462A4 (en) | Anti-tim-3 antibodies | |
| CA3278826A1 (en) | Her-2 binding antibodies | |
| EP4070816A4 (en) | Anti-gdf15 antibody | |
| CA3261708A1 (en) | Antibodies binding to clec12a | |
| HK40078572A (en) | Protein binders to irhom2 epitopes | |
| HK40051043A (en) | Antibodies binding to ilt4 | |
| HK40079557A (en) | Novel anti-fgfr2b antibodies | |
| HK40079556A (en) | Novel anti-fgfr2b antibodies | |
| HK40079559A (en) | Novel anti-fgfr2b antibodies | |
| HK40078248A (en) | Heavy chain antibodies binding to cd38 | |
| HK40091677A (en) | Antibodies to tigit | |
| HK40056602A (en) | Heavy chain antibodies binding to cd38 | |
| HK40041674A (en) | Novel anti-sirpa antibodies | |
| HK40068892A (en) | Heavy chain antibodies binding to psma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - DIVISIONAL Effective date: 20240712 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240712 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| A18 | Application divided or continuation or continuation in part accepted |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A18-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DIVISIONAL REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250201 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250201 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250201 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250325 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250521 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250521 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20250528 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250627 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250704 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20251125 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20251125 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION) Effective date: 20251129 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251201 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251229 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED Effective date: 20260416 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260422 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260422 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260422 |